Key result
A single timepoint 12-lead ECG screening identified new atrial fibrillation in 0.2% of a middle-aged German cohort, with cost-effectiveness potentially reached in individuals aged 65 years and older.
Why the study?
Little is known about the optimal screening population for detecting new atrial fibrillation in the community.
Is single timepoint 12-lead ECG screening for atrial fibrillation cost-effective in a general population cohort?
Cohort (n=15,010)
Is single timepoint 12-lead ECG screening for atrial fibrillation cost-effective in a general population cohort?
Single timepoint ECG screening for atrial fibrillation may be cost-effective in individuals aged 65 years and older, but is not improved by NT-proBNP prescreening.
Answers are grounded in this paper and cite their sources.
May support targeted ECG screening in adults 65-74 years; leaves open need for RCTs to confirm outcomes and adoption.
OBJECTIVE: Little is known on optimal screening population for detecting new atrial fibrillation (AF) in the community. We describe characteristics and estimate cost-effectiveness for a single timepoint electrocardiographic screening. METHODS: We performed a 12-lead ECG in the German population-based Gutenberg Health Study between 2007 and 2012 (n=15 010), mean age 55±11 years, 51% men and collected more than 120 clinical and biomarker variables, including N-terminal pro B-type natriuretic peptide (Nt-proBNP), risk factors, disease symptoms and echocardiographic variables. RESULTS: Of 15 010 individuals, 466 (3.1%) had AF. New AF was found in 32 individuals, 0.2% of the total sample, 0.5% of individuals aged 65-74 years and predominantly men (86%). The classical risk factor burden was high in individuals with new AF. The median estimated stroke risk was 2.2%/year, while risk of developing heart failure was 21% over 10 years. In the 65-74 year age group, the cost per quality-adjusted life-year gained resulting from a single timepoint screening was €30 361. In simulations, the costs were highly sensitive to AF detection rates, proportion of treatment and type of oral anticoagulant. Prescreening by Nt-proBNP measurements was not cost-effective in the current setting. CONCLUSIONS: In our middle-aged population cohort, we identified 0.2% new AF by single timepoint screening. There was a significant estimated risk of stroke and heart failure in these individuals. Cost-effectiveness for screening may be reached in individuals aged 65 years and older. The simple age cut-off is not improved by using Nt-proBNP as a biomarker to guide a screening programme.
No takes yet. Share an insight, caveat, or question.
Schnabel et al. (2021) conducted a cohort in Atrial fibrillation (n=15,010). Single timepoint 12-lead ECG screening was evaluated on Detection of new atrial fibrillation. A single timepoint 12-lead ECG screening identified new atrial fibrillation in 0.2% of a middle-aged German cohort, with cost-effectiveness potentially reached in individuals aged 65 years and older.
Synapse has enriched 10 related papers. Consider them for comparative context: